Publications

Kapoor et al. have highlighted the gap to be bridged in terms of management of co-mutations in advanced non-small cell lung carcinoma (NSCLC).[1] Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) mutations occur in the helical-binding domain and the catalytic subunit of the protein. These rearrangements have tumorigenic potential and impart resistance to treatment.[2] PIK3CA (exons 9 and 20) mutations generally exist in conjunction with other molecular alterations in genes such as the epidermal growth factor receptor (EFGR), Kirsten rat sarcoma virus (KRAS), anaplastic lymphoma kinase (ALK), and phosphatase and tensin analog (PTEN).[34]